Thursday, September 8, 2011

Amgen Backs Therapeutic Antibody Firm

Thousand Oaks-based biotech giant Amgen has backed a developer of therapeutic antibodies, via its venture capital arm, Amgen Ventures. According to Seattle-based Theraclone Sciences, Amgen Ventures was one of the investors in a $10.6M, Series B extension round for the company. Theraclone is developing therapeutic antibodies for treating infectious disease and cancer. Other investors in the round were ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, and Zenyaku Kogyo. More information »